New York-based medication delivery startup NextMed has drawn criticism
from health professionals over its advertisements, which lack drug-risk
information and reportedly promoted drugs for unapproved uses.
NextMed reportedly faked client reviews and published fake testimonials
on its website. The startup is under fire from the public for failing to
provide clients with requested services.
- NextMed was promoting drugs such as Ozempic, Wegovy, and Mounjaro for weight loss.
- Ozempic
and Mounjaro are diabetes drugs that are not approved for weight loss
purposes by the U.S. Food and Drug Administration.
- After
the WSJ questioned the startup about the issues, NextMed stopped
running all its television ads and changed the content of its website.
- Their commercials, which aired on Fox News, ESPN, and MSNBC, were seen 99 million times.
- The firm has reportedly raised $7M in funding to date and generated nearly $10M in revenue in 2022.
- NextMed was trying to raise a $30M funding round.
